EP0659419A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
2-Phenyl-3-azoylthiophenes for inhibiting breast disorders
Assignee: Eli Lilly and Co
•
Filing: 1994-12-19
•
Granted: —
•
Expires: 2014-12-19
Abstract
Abstract A method of inhibiting breast disorders administering to a human in need of treatment an effective amount of a compound having the formula wherein R¹ and R³ are independently hydrogen, -CH₃, wherein Ar is optionally substituted phenyl; R² is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
Inventors
- 👤 James Joseph Sales
- 👤 George Joseph Cullinan
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 09:57
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/4523; A61K31/4535; A61K31/40; A61K31/38; A61K31/4025; A61K31/55; A61P; A61P13/00; A61P13/02; A61P15/00; A61P35/00; C; C07; C07D; C07D409/00; C07D409/02; C07D409/10
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
52 words
The use of a compound having the formula wherein R¹ and R³ are independently hydrogen, -CH₃, wherein Ar is optionally substituted phenyl; R² is selected from the group consisting of pyrrolidino and piperidino; or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament useful for inhibiting breast disorders.
Claim 2
Dependent Claim
13 words
The use of Claim 1 wherein said compound is the hydrochloride salt thereof.
Claim 3
Dependent Claim
10 words
The use of Claim 1 wherein said medicament is prophylactic.
Claim 4
Dependent Claim
13 words
The use of Claim 1 wherein said compound is or its hydrochloride salt.
Claim 5
Dependent Claim
19 words
The use of Claim 1 wherein said breast disorder is selected from gynecomastia, galactorrhea, non-fibrocystic, non-cancerous mastodynia and mastophathy.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.